FY 18 guidance maintained but no respite on the horizon
12/07/18 -"In its Q1 18 trading update, Hikma put on a brave face and maintained its FY 18 guidance – group level. The injectables business is expected to deliver sales of $750-800m, but the core operating ..."
Pages
50
Language
English
Published on
12/07/18
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated